Olawale Akinmerese, MD
Family Medicine · Fort Worth, TXNPI 1194918649
Payments from drug & device makers
Across 132 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$320
- Otsuka America Pharmaceutical, Inc.$220
- Neurocrine Biosciences, Inc.$170
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$162
- Lilly USA, LLC$151
- UCB, Inc.$150
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,343100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 25 | $320 |
| Otsuka America Pharmaceutical, Inc. | 12 | $220 |
| Neurocrine Biosciences, Inc. | 7 | $170 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $162 |
| Lilly USA, LLC | 10 | $151 |
| UCB, Inc. | 6 | $150 |
| Lundbeck LLC | 8 | $145 |
| Teva Pharmaceuticals USA, Inc. | 5 | $118 |
| Novo Nordisk | 7 | $107 |
| Alkermes, Inc. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $83 |
| Bayer | 4 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Paratek Pharmaceuticals, Inc. | 3 | $61 |
| Johnson & Johnson | 3 | $57 |
| Pfizer | 3 | $53 |
| Eisai Inc. | 2 | $49 |
| Novartis | 3 | $49 |
| SK Life Science, Inc. | 2 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $29 |
| AstraZeneca | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Integra Lifesciences Corporation | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Mylan Specialty L.p. | 1 | $15 |
| CMP Pharma, Inc. | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| KCI USA, Inc. | 1 | $12 |
| Smith+Nephew | 1 | $11 |
How this compares
$2,343 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,131 | $339,904 |
| SantylCollagenase Clostridium Hist. | 17 | $249,563 |
| AustedoDeutetrabenazine | 46 | $139,709 |
| Austedo XrDeutetrabenazine | 45 | $139,641 |
| JardianceEmpagliflozin | 324 | $130,472 |
| XifaxanRifaximin | 76 | $110,881 |
| TradjentaLinagliptin | 151 | $81,106 |
| MounjaroTirzepatide | 54 | $76,440 |
| OzempicSemaglutide | 65 | $72,345 |
| IngrezzaValbenazine Tosylate | 20 | $65,787 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 15 | $60,688 |
| TrulicityDulaglutide | 95 | $56,054 |
| JanuviaSitagliptin Phosphate | 161 | $50,856 |
| JulucaDolutegravir/Rilpivirine | 17 | $43,509 |
| GemtesaVibegron | 159 | $38,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $339,9041,131 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $118 | $279,35091 claims |
| Smith+NephewSantyl | $11 | $249,56317 claims |
| Lilly USA, LLCMounjaro, Trulicity | $151 | $132,494149 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $162 | $110,88176 claims |
| Novo NordiskOzempic | $107 | $72,34565 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $170 | $65,78720 claims |
| Johnson & JohnsonInvega Sustenna, Xarelto | $57 | $64,206113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $29 | $38,994159 claims |
| AstraZenecaLokelma, Breztri Aerosphere | $22 | $35,93483 claims |
| NovartisEntresto | $49 | $18,73055 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $13 | $17,93032 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.